Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIA-Lung: Adaptive vs Non-Adaptive RT in Stage III NSCLC
NCT05488626Withdrawn
- Sponsor
- Varian Medical Systems
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in non-small cell lung cancer (NSCLC), sponsored by Varian Medical Systems. Primary endpoint: Acute toxicity at 90 days. Planned start Oct 2022; status: withdrawn.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05488626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488626.